Skip to main content
      Complications of Covid19 in Lupus: Dr. Kathryn Dao ( @KDAO2011) discusses abstract #1933 presented at the #ACR21 annual

      Dr. John Cush RheumNow

      3 years 1 month ago
      Complications of Covid19 in Lupus: Dr. Kathryn Dao ( @KDAO2011) discusses abstract #1933 presented at the #ACR21 annual meeting. https://t.co/jKFJwCBeCo https://t.co/ncleyYZWLn
      RT @DrPetryna: Abst1830 #ACR21 @RheumNow d/c of TNFi in PsA/PSO: probability of d/c TNFi ⬆️ by 9.6% for each additio

      Olga Petryna DrPetryna

      3 years 1 month ago
      Abst1830 #ACR21 @RheumNow d/c of TNFi in PsA/PSO: probability of d/c TNFi ⬆️ by 9.6% for each additional biologic trial. Former smoker &PsA duration correlated w/ discontinuation. most commonly reason for d/c TNFi was secondary failure (33%). infliximab had lower d/c rate https://t.co/BXd2ALX2qo
      RT @ericdeinmd: #ACR21 L17: Heterologous vs Homologous Booster vax
      ▶️RTX non-responders to mRNA: Randomized to mRNA

      Eric Dein ericdeinmd

      3 years 1 month ago
      #ACR21 L17: Heterologous vs Homologous Booster vax ▶️RTX non-responders to mRNA: Randomized to mRNA 3rd dose vs AZ vax ⭐️Majority of pts develop immune response (humoral and/or cellular) after 3rd dose, no statistical diff b/w groups @Rheumnow https://t.co/cuM9LcEr4u https://t.co/cmNBNSIoOl
      RT @Janetbirdope: What to do w Rituximab users and #COVID19 vaccine? #Rituximab no seroconversion 30% with 2 #COVIDVacci

      Janet Pope Janetbirdope

      3 years 1 month ago
      What to do w Rituximab users and #COVID19 vaccine? #Rituximab no seroconversion 30% with 2 #COVIDVaccination. With 3rd vaccine dose up to 94% can have immune response! Pts need their 3rd vaccination @RheumNow #ACR21 #ACRBest abstL17 https://t.co/0GHOuoqPKQ
      RT @synovialjoints: Deucravacitinib is a novel, oral, selective TYK2 inhibitor in PsA and selectively mediates specific

      Dr. Antoni Chan synovialjoints

      3 years 1 month ago
      Deucravacitinib is a novel, oral, selective TYK2 inhibitor in PsA and selectively mediates specific inflammatory pathways (IL-23, IL-12, Type I IFN). Listen to my interview with Prof. Oliver Fitzgerald on this and his highlights https://t.co/3UJCwbHsLC @RheumNow #ACR21 Abst#490 https://t.co/OWZDHhcQ9q
      RT @uptoTate: Racial disparities & Co-morbidities in PsA findings. Amongst important others, increased biologic use

      Dr. Rachel Tate uptoTate

      3 years 1 month ago
      Racial disparities & Co-morbidities in PsA findings. Amongst important others, increased biologic use in Caucasians w/ PsA vs DMARDs in black PsA pts. View Abs 1780 for other relevant findings. #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/0uKsa8i0bG https://t.co/R9YkxYqXws
      RT @KDAO2011: 👉29% of pts on RTX fail to mount a humoral OR cellular response to #COVIDvaccine & have⬆️hosp,â

      TheDaoIndex KDAO2011

      3 years 1 month ago
      👉29% of pts on RTX fail to mount a humoral OR cellular response to #COVIDvaccine & have⬆️hosp,⬆️hosp stay,⬆️severity, persistent viremia,⬆️deaths) 👉study adding booster (AZ or mRNA) overcomes this, enhancing humoral and cellular response #ACR21 @rheumnow Abst#L17 https://t.co/yuX1TT6ZBF
      Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS) took the centre stage when it was first introduced at ACR20 last year. It got everyone’s thinking that they might have encountered one or two patients in their rheumatology lifetime who might have this condition. One year on, more cases have been reported and this article summarises some breakthroughs pertaining to research in VEXAS.
      Work participation in patients with axSPA

      Patients w/ axSpA often have increased absence from work as well as reduced p

      Dr. John Cush RheumNow

      3 years 1 month ago
      Work participation in patients with axSPA Patients w/ axSpA often have increased absence from work as well as reduced productivity at work, which can lead to wider economic & social burden. Dr. Dey (@DrMiniDey) discusses abstracts from #ACR21. https://t.co/eAMLPR2zoT https://t.co/NuIajGa7gx
      RT @doctorRBC: Methotrexate did not improve Ustekinumab efficacy in tx of PsA
      ⭐️Addition of MTX did not improve dact

      Robert B Chao, MD doctorRBC

      3 years 1 month ago
      Methotrexate did not improve Ustekinumab efficacy in tx of PsA ⭐️Addition of MTX did not improve dactylitis, enthesitis, skin, QoL or function #ACR21 #ACRBest @RheumNow Abs#L12 https://t.co/6dxWPNskou https://t.co/BnzH8PfaMV
      RT @AkhilSoodMD: Very interesting talk Abst L16
      Singh & colleagues found that patients with rheumatic diseases are a

      Akhil Sood MD AkhilSoodMD

      3 years 1 month ago
      Very interesting talk Abst L16 Singh & colleagues found that patients with rheumatic diseases are at increased risk for breakthrough infxn - Recent drug exposure and certain medication type can influence outcomes - Findings support need for 3rd dose in RD pts #ACR21 @RheumNow https://t.co/vU6ZNIEWbc
      Traditionally telemedicine is thought to be a technology where a patient directly talks to a provider or a specialist; however, another concept of having a patient with a local primary care who in turn accesses specialists via video conferencing, is gaining some momentum.  
      RT @uptoTate: Prevalent drug utilization unrelated to enthesitis in PsA. Pts on cDMARDs had higher physician globals vs

      Dr. Rachel Tate uptoTate

      3 years 1 month ago
      Prevalent drug utilization unrelated to enthesitis in PsA. Pts on cDMARDs had higher physician globals vs those treated w/TNFi & IL-17i. In aggregate, no pattern of dz activity scores correlation w/drugs. Abs 1782 #ACR21 #RheumNow @RheumNow @doctorRBC https://t.co/x57BkBjpjo https://t.co/QmdXqOxLki
      RT @doctorRBC: Phase 2 trial of tildrakizumab (IL-23i) for the treatment of PsA showed lower efficacy in pts with metabo

      Robert B Chao, MD doctorRBC

      3 years 1 month ago
      Phase 2 trial of tildrakizumab (IL-23i) for the treatment of PsA showed lower efficacy in pts with metabolic syndrome compared to those without #ACR21 @RheumNow Abs#1819 https://t.co/GYHbiH9NSW https://t.co/YGcZcITjzj
      RT @KDAO2011: USA EMR (N3C) Data on 577,335 Rheum Pts w/18,164 #COVID19 breakthrough infx (BTI)
      👉91% vax'd
      👉3.1%

      TheDaoIndex KDAO2011

      3 years 1 month ago
      USA EMR (N3C) Data on 577,335 Rheum Pts w/18,164 #COVID19 breakthrough infx (BTI) 👉91% vax'd 👉3.1% w/BTI 👉86% were vax'd May 2021 or earlier 👉More BTI w/Pfizer 👉BTI higher in inflamm myositis, RA 👉Drugs assc w/BTI: biologics, mult DMARDs #ACR21 @rheumnow Abst#L16 #ACRbest https://t.co/Eu77vAAk3N
      ×